Immunization against leishmaniasis by PLGA nanospheres loaded with an experimental autoclaved Leishmania major (ALM) and Quillaja saponins

Tropical Biomedicine

Volumn 27, Issue 3, 2010, Pages 639-650

  Tafaghodi, M ^a   Eskandari, M ^a   Kharazizadeh, M ^a   Khamesipour, A ^b   Jaafari, M R ^a  

^a MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOCLAVED LEISHMANIA MAJOR VACCINE; DRUG CARRIER; GAMMA INTERFERON; IMMUNOGLOBULIN G; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 4; LACTIC ACID; LEISHMANIA VACCINE; NANOSPHERE; POLYGLYCOLIC ACID; POLYLACTIC ACID POLYGLYCOLIC ACID COPOLYMER; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER; PROTOZOON ANTIBODY; SAPONIN;

ANIMAL; ARTICLE; BAGG ALBINO MOUSE; BLOOD; CHEMISTRY; DRUG DELIVERY SYSTEM; FEMALE; FOOT; IMMUNIZATION; IMMUNOLOGY; LEISHMANIASIS; METHODOLOGY; MONONUCLEAR CELL; MOUSE; PATHOLOGY; QUILLAJA; SCANNING ELECTRON MICROSCOPY; SECRETION; ULTRASTRUCTURE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, PROTOZOAN; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; FEMALE; FOOT; IMMUNIZATION; IMMUNOGLOBULIN G; INTERFERON-GAMMA; INTERLEUKIN-4; LACTIC ACID; LEISHMANIASIS; LEISHMANIASIS VACCINES; LEUKOCYTES, MONONUCLEAR; MICE; MICE, INBRED BALB C; MICROSCOPY, ELECTRON, SCANNING; NANOSPHERES; POLYGLYCOLIC ACID; QUILLAJA; SAPONINS;

EID: 78650767560     PISSN: 01275720     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Ahsan, F., Rivas, I.P., Khan, M.A. & Torres Suarez, A.I. (2002). Targeting to macrophages: Role of physicochemical properties of particulate carriers -liposomes and microspheres -on the phagocytosis by macrophages. Journal of Controlled Release 79(1-3): 29-40.
2. Alimohammadian, M.H., Khamesipour, A., Darabi, H., Firooz, A., Malekzadeh, S., Bahonar, A., Dowlati, Y. & Modabber, F. (2002). The role of Bcg in human immune responses induced by multiple injections of autoclaved Leishmania major as a candidate vaccine against leishmaniasis. Vaccine 21(3-4): 174-180.
3. Badiee, A., Jaafari, M.R. & Khamesipour, A. (2007). Leishmania major: Immune response in Balb/C mice immunized with stress-inducible protein 1 encapsulated in liposomes. Experimental Parasitology 115(2): 127-134.
4. Bahar, K., Dowlati, Y., Shidani, B., Alimohammadian, M.H., Khamesipour, A., Ehsasi, S., Hashemi-Fesharki, R., Ale-Agha, S. & Modabber, F. (1996). Comparative safety and immunogenicity trial of two killed Leishmania major vaccines with or without Bcg in human volunteers. Clinics in Dermatology 14(5): 489-495.
5. Cleland, J.L., Powell, M.F., Lim, A., Barron, L., Berman, P.W., Eastman, D.J., Nunberg, J.H., Wrin, T. & Vennari, J.C. (1994). Development of a single-shot subunit vaccine for Hiv-1. AIDS Research and Human Retroviruses 10(SUPPL. 2).
6. Cox, J.C. & Coulter, A.R. (1997). Adjuvants -a classification and review of their modes of action. Vaccine 15(3): 248-256.
7. Diwan, M., Khar, R.K. & Talwar, G.P. (2001). Tetanus toxoid loaded 'Preformed Microspheres' of cross-linked dextran. Vaccine 19(28-29): 3853-3859.
8. Diwan, M., Tafaghodi, M. & Samuel, J. (2002). Enhancement of immune responses by Co-delivery of a Cpg oligodeoxynucleotide and tetanus toxoid in biodegradable nanospheres. Journal of Controlled Release 85(1-3): 247-262.
9. Ellis, J.A., West, K.H., Waldner, C. & Rhodes, C. (2005). Efficacy of a saponinadjuvanted inactivated respiratory syncytial virus Vaccine in Calves, The Canadian Veterinary Journal 46(2): 155-162.
10. Glaueri, A.M., Dingle, J.T. & Lucy, J.A. (1962). Action of saponins on biological membranes, Nature 196: 953.
11. Gupta, R.K. & Siber, G.R. (1995). Adjuvants for human vaccines -current status, problems and future pospects. Vaccine 13(14): 1263-1276. http://www.who.org.
12. Huber, M., Baier, W., Bessler, W.G. & Heinevetter, L. (2002). Modulation of the Th1/Th2 bias by lipopeptide and saponin adjuvants in orally immunized mice. Immunobiology 205(1): 61-73.
13. Jaafari, M.R., Badiee, A., Khamesipour, A., Samiei, A., Soroush, D., Kheiri, M.T., Barkhordari, F., McMaster, W.R. & Mahboudi, F. (2007). The role of Cpg Odn in enhancement of immune response and protection in Balb/C mice immunized with recombinant major surface glycoprotein of Leishmania (Rgp63) encapsulated in cationic liposome. Vaccine 25(32): 6107-6117.
14. Jaafari, M.R., Ghafarian, A., Farrokh-Gisour, A., Samiei, A., Kheiri, M.T., Mahboudi, F., Barkhordari, F., Khamesipour, A. & McMaster, W.R. (2006). Immune response and protection assay of recombinant major surface glycoprotein of Leishmania (Rgp63) reconstituted with liposomes in Balb/C mice. Vaccine 24(29-30): 5708-5717.
15. Javadian, E., Nadim, A., Tahvildare-Bidruni, G. & Assefi, V. (1976). Epidemiology of cutaneous leishmaniasis in Iran: B. Khorassan Part V: Report on a focus of zoonotic cutaneous leishmaniasis in Esferayen. Bulletin de la Societe de Pathologie Exotique et de Ses Filiales 69(2): 140-143.
16. Johansen, P., Men, Y., Merkle, H.P. & Gander, B. (2000). Revisiting Pla/Plga microspheres: An analysis of their potential in parenteral vaccination. European Journal of Pharmaceutics and Biopharmaceutics 50(1): 129-146.
17. Kamil, A.A., Khalil, E.A., Musa, A.M., Modabber, F., Mukhtar, M.M., Ibrahim, M.E., Zijlstra, E.E., Sacks, D., Smith, P.G., Zicker, F. & El-Hassan, A.M. (2003). Alum-precipitated autoclaved Leishmania major plus Bacille Calmette-Guerrin, a candidate vaccine for visceral leishmaniasis: safety, skindelayed type hypersensitivity response and dose finding in healthy Volunteers. Transactions of the Royal Society of Tropical Medicine and Hygiene 97(3): 365-368.
18. Kensil, C.R. (1996). Saponins as vaccine adjuvants. Critical Reviews in Therapeutic Drug Carrier Systems 13(1-2): 1-55.
19. Kensil, C.R., Wu, J.Y. & Soltysik, S. (1995). Structural and immunological characterization of the vaccine adjuvant Qs- 2.1. Pharmaceutical Biotechnology 6: 525-541.
20. Keshavarz Valian, H., Khoshabe Abdollah Kenedy, L., Nateghi Rostami, M., Miramin Mohammadi, A. & Khamesipour, A. (2008). Role of Mycobacterium vaccae in the Protection Induced by First Generation Leishmania Vaccine against Murine Model of Leishmaniasis. Parasitology Research 103: 21-28.
21. Khamesipour, A., Rafati, S., Davoudi, N., Maboudi, F. & Modabber, F. (2006). Leishmaniasis vaccine candidates for development: A global overview, Indian Journal of Medical Research 123(3): 423-438.
22. Lacaille-Dubois, M.A. (1999). Saponins as immunoadjuvants and immunostimulants. In: immunomodulatory agents from plants, ed. Wagner, H. Switzerland: Birkhauser Verlag, 243-272.
23. Lycke, N. (2007). Mechanisms of adjuvant action. In: Vaccine adjuvants and delivery systems, ed. Singh, M. New Jersey: John Wiley & Sons, Inc., 53-79.
24. Marciani, D.J., Pathak, A.K., Reynolds, R.C., Seitz, L. & May, R.D. (2001). Altered immunomodulating and toxicological properties of degraded Quillaja saponaria molina saponins. International Immunopharmacology 1(4): 813-818.
25. Marciani, D.J., Press, J.B., Reynolds, R.C., Pathak, A.K., Pathak, V., Gundy, L.E., Farmer, J.T., Koratich, M.S. & May, R.D. (2000). Development of semisynthetic triterpenoid saponin derivatives with immune stimulating activity. Vaccine 18(27): 3141-3151.
26. Modabber, F. (1995). Vaccines against leishmaniasis. Annals of Tropical Medicine and Parasitology 89(Supplement 1): 83-88.
27. Mohaghegh, M. & Tafaghodi, M. (2010). Dextran microspheres could enhance immune responses against plga nanospheres encapsulated with Tetanus toxoid and Quillaja Saponins after nasal immunization in rabbit. Pharmaceutical Development and Technology DOI:10.3109/10837450903479962.
28. Mohebali, M., Khamesipour, A., Mobedi, I., Zarei, Z. & Hashemi-Fesharki, R. (2004). Double-blind randomized efficacy field trial of alum precipitated autoclaved Leishmania major vaccine mixed with bcg against canine visceral leishmaniasis in Meshkin-Shahr District, I.R. Iran. Vaccine 22(29-30): 4097-4100.
29. Newman, K.D., Elamanchili, P., Kwon, G.S. & Samuel, J. (2002). Uptake of poly(d,llactic- co-glycolic acid) microspheres by antigen-presenting cells in vivo. Journal of Biomedical Materials Research 60(3): 480-486.
30. Newman, K.D., Sosnowski, D.L., Kwon, G.S. & Samuel, J. (1998). Delivery of Muc1 Mucin peptide by poly(D,L-Lactic-Co- Glycolic Acid) microspheres induces type 1 t helper immune responses. Journal of Pharmaceutical Sciences 87(11): 1421-1427.
31. Noazin, S., Khamesipour, A., Moulton, L.H., Tanner, M., Nasseri, K., Modabber, F., Sharifi, I., Khalil, E.A., Bernal, I.D., Antunes, C.M. & Smith, P.G. (2009). Efficacy of killed whole-parasite vaccines in the prevention of leishmaniasis: A meta-analysis, Vaccine 27(35): 4747-4753.
32. Noazin, S., Modabber, F., Khamesipour, A., Smith, P.G., Moulton, L.H., Nasseri, K., Sharifi, I., Khalil, E.A., Bernal, I.D., Antunes, C.M., Kieny, M.P. & Tanner, M. (2008). First Generation leishmaniasis vaccines: A review of field efficacy trials. Vaccine 26(52): 6759-6767.
33. Palatnik-de-Sousa, C.B. (2008). Vaccines for leishmaniasis in the fore coming 25 years. Vaccine 26(14): 1709-1724.
34. Rafati, S., Gholami, E., Hassani, N., Ghaemimanesh, F., Taslimi, Y., Taheri, T. & Soong, L. (2007). Leishmania major heat shock protein 70 (hsp70) is not protective in murine models of cutaneous leishmaniasis and stimulates strong humoral responses in cutaneous and visceral leishmaniasis patients.Vaccine 25(21): 4159-4169.
35. Rebelatto, M.C., Guimond, P., Bowersock, T.L. & Hogen, E.H. (2001). Induction of systemic and mucosal immune response in cattle by intranasal administration of pig serum albumin in alginate microparticles. Veterinary Immunology and Immunopathology 83(1-2): 93-105.
36. Sacks, D. & Noben-Trauth, N. (2002). The immunology of susceptibility and resistance to Leishmania Major in mice. Nature Reviews Immunology 2(11): 845-858.
37. Sajadi Tabassi, S.A., Tafaghodi, M. & Jaafari, M.R. (2008). Induction of high antitoxin titers against Tetanus toxoid in rabbits by intranasal immunization with dextran microspheres, International Journal of Pharmaceutics 360(1-2): 12-17.
38. Santos, F.N., Borja-Cabrera, G.P., Miyashiro, L.M., Grechi, J., Reis, A.B., Moreira, M.A.B., Martins Filho, O.A., Luvizotto, M.C.R., Menz, I., Pessôa, L.M., Gonçalves, P.R., Palatnik, M. & Palatnik-de-Sousa, C.B. (2007). Immunotherapy against experimental canine visceral leishmaniasis with the saponin enriched-leishmune® vaccine. Vaccine 25(33): 6176-6190.
39. Santos, W.R., de Lima, V.M.F., de Souza, E.P., Bernardo, R.R., Palatnik, M. & de Sousa, C.B.P. (2002). Saponins, Il12 and Bcg adjuvant in the fml-vaccine formulation against murine visceral leishmaniasis. Vaccine 21(1-2): 30-43.
40. Scott, P., Pearce, E., Natovitz, P. & Sher, A. (1987). Vaccination against cutaneous leishmaniasis in a murine model. I. Induction of protective immunity with a soluble extract of promastigotes. Journal of Immunology 139(1): 221-227.
41. Shimizu, Y., Yamakami, K., Gomi, T., Nakata, M., Asanuma, H., Tadakuma, T. & Kojima, N. (2003). Protection against Leishmaniam major infection by oligomannose-coated liposomes. Bioorganic and Medicinal Chemistry 11(7): 1191-1195.
42. Singh, M. & O'Hagan, D. (1999). Advances in vaccine adjuvants. Nature Biotechnology 17(11): 1075-1081.
43. Singh, M. & O'Hagan, D.T. (2003). Recent advances in veterinary vaccine adjuvants. International Journal for Parasitology 33(5-6): 469-478.
44. Sjölander, A., Drane, D., Maraskovsky, E., Scheerlinck, J.-P., Suhrbier, A., Tennent, J. & Pearse, M. (2001). Immune responses to Iscom® formulations in animal and primate model. Vaccine 19(17-19): 2661-2665.
45. Soltysik, S., Wu, J.-Y., Recchia, J., Wheeler, D.A., Newman, M.J., Coughlin, R.T. & Kensil, C.R. (1995). structure/function studies of Qs-21 adjuvant: assessment of triterpene aldehyde and glucuronic acid roles in adjuvant function. Vaccine 13(15): 1403-1410.
46. Song, X. & Hu, S. (2009). Adjuvant activities of saponins from traditional chinese medicinal herbs. Vaccine 27(36): 4883-4890.
47. Tafaghodi, M., Tabassi, S.A.S., Jaafari, M.-R., Zakavi, S.R. & Momen-nejad, M. (2004). Evaluation of the clearance characteristics of various microspheres in the human nose by gamma-scintigraphy. International Journal of Pharmaceutics 280(1-2): 125-135.
48. Venkataprasad, N., Coombes, A.G.A., Singh, M., Rohde, M., Wilkinson, K., Hudecz, F., Davis, S.S. & Vordermeier, H.M. (1999). Induction of cellular immunity to a mycobacterial antigen adsorbed on lamellar particles of lactide polymers. Vaccine 17(15-16): 1814-1819.
49. Waterborg, J.H. (2002). Quantitation of proteins. In: The Protein Protocols Handbook, (Editor, Walker) Humana Press, 3-36 New Jersey:
50. Xie, Y., Sun, H.-X. & Li, D. (2009). Platycodin d is a potent adjuvant of specific cellular and humoral immune responses against recombinant hepatitis B antigen, Vaccine 27(5): 757-764.
51. Yang, Z., Chen, A., Sun, H., Ye, Y. & Fang, W. (2007). Ginsenoside Rd elicits Th1 and Th2 immune responses to ovalbumin in mice. Vaccine 25(1): 161-169.
52. Zhang, P., Yang, Q.-B., Marciani, D.J., Martin, M., Clements, J.D., Michalek, S.M. & Katz, J. (2003). Effectiveness of the Quillaja saponin semi-synthetic analog Gpi-0100 in potentiating mucosal and systemic responses to recombinant Hagb from porphyromonas Gingivalis. Vaccine 21(27-30): 4459-4471.